客服中心
關(guān)注我們
全國服務(wù)熱線：
18086415513
賽培新增產(chǎn)品文章：人IL-17 ELISA試劑盒
發(fā)布時間：2022-09-16 16:52:55
組合型人工肝治療對慢加急性肝功能衰竭患者血清IL-17的影響研究
朱立娜 黃初軍 趙秋燕 尹春萍 唐 源* （曲靖市第一人民醫(yī)院消化內(nèi)科，云南 曲靖 655000） 【摘要】目的 探討組合型人工肝治療對慢加急性肝功能衰竭（ACLF）患者血清白細(xì)胞介素 -17（IL-17）的影響。方法 采用流式細(xì)胞儀檢 測肝損傷組、ACLF 組血清 IL-17 的濃度含量，進(jìn)一步檢測 ACLF 患者進(jìn)行血漿置換（PE）、雙重血漿吸附（DPMAS）、血漿置換 + 雙重 血漿吸附（PE+DPMAS）治療后的濃度，對比 3 組治療前、治療后指標(biāo)變化。結(jié)果 ACLF 患者血清 IL-17 與肝損傷組比較有顯著性差異 （P ＜ 0.05）。ACLF 患者進(jìn)行人工肝不同模式治療比較 ：PE 組患者治療前后 IL-17 的水平比較有統(tǒng)計(jì)學(xué)意義（P ＜ 0.05）。DPMAS 組 患者治療前后 IL-17 濃度含量比較差異有統(tǒng)計(jì)學(xué)意義（P ＜ 0.05）。PE+DPMAS 組患者治療前后 IL-17 含量比較差異有統(tǒng)計(jì)學(xué)意義 （P ＜ 0.05）。PE 組、DPMAS 組、PE+DPMAS 組患者治療前 IL-17 濃度差異無統(tǒng)計(jì)學(xué)意義（P ＞ 0.05）；3 組治療后比較 ：PE+DPMAS 組 與 PE 組、DPMAS 組間 IL-17 濃度差異有統(tǒng)計(jì)學(xué)意義（P ＜ 0.05）。PE 組與 DPMAS 組比較 IL-17 濃度差異有統(tǒng)計(jì)學(xué)意義（P ＜ 0.05）。 結(jié)論 ① ACLF 患者 IL-17 濃度高于肝損傷組。② PE 組、DPMAS 組、PE+DPMAS 組患者治療 ACLF 均可以有效清除 IL-17。其中 PE+DPMAS 治療模式對 ACLF 患者血清 IL-17 的清除效果明顯優(yōu)于 PE 和 DPMAS 治療組，DPMAS 組清除 IL-17 的能力優(yōu)于 PE 組。 【關(guān)鍵詞】人工肝 ；肝功能衰竭 ；白細(xì)胞介素 -17 中圖分類號：R575.3? ? ? ? ? 文獻(xiàn)標(biāo)識碼：B? ? ? ? ? ? 文章編號：1671-8194（2021）15-0031-03
Effect of Different Modes of Artificial Liver Therapy on Serum IL-17 in Patients with Acute-on-chronic Liver Failure
ZHU Li'na, HUANG Chujun, ZHAO Qiuyan, YIN Chunping, TANG Yuan* (Department of Digestive Medicine, Qujing First People's Hospital, Qujing 655000, China) [Abstract] Objective To investigate the effects of different modes of artifificial liver therapy on serum interleukin-17(IL-17) in patients with acute-on-chronic liver failure (ACLF). Methods Flow cytometry was used to detect the serum IL-17 concentration in the liver injury group and ACLF group, and to further detect plasma exchange (PE), dual plasma adsorption (DPMAS), plasma exchange + dual plasma adsorption (PE+DPMAS) treatments in ACLF patients after the concentration, compare the index changes of the three groups before and after treatment. Results There was a signifificant difference between serum IL- 17 and liver injury in patients with ACLF(P＜0.05). The comparison of different modes of artifificial liver therapy in patients with ACLF: the differences of serum IL-17 between the pre-and post-treatment of PE group was statistically signifificant(P＜0.05). The differences of serum IL-17 before and after treatment of DPMAS group was statistically signifificant(P＜0.05). The differences of serum IL-17 before and after treatment of PE+DPMAS group was statistically signifificant(P＜0.05). There were no signifificant differences of serum IL-17 between PE group, DPMAS group and PE+DPMAS group before treatment (P＞0.05). After the three groups of treatment, the differences of serum IL-17 between the PE + DPMAS group and the PE group and the DPMAS group was signifificant and statistically signifificant(P＜0.05). The differences of serum IL-17 between PE group and DPMAS group was statistically signifificant(P＜0.05). Conclusion The concentration of cytokine IL-17 in ACLF patients is higher than that in liver injury group. The treatment of acute-on-chronic liver failure in PE group, DPMAS group and PE+DPMAS group could effectively remove the cytokine IL-17. The removal effect of PE+DPMAS treatment model on serum IL-17 in ACLF patients is signifificantly better than that of PE and DPMAS treatment group. The ability of the DPMAS group to clear IL-17 is better than that of the PE group. [Key words] Artifificial liver; Liver failure; Interleukin-17
組合型人工肝治療對慢加急性...者血清IL-17的影響研究_朱立娜.pdf
